Rilzabrutinib治疗天疱疮的PEGASUS 3期随机研究疗效与安全性
PEGASUS 3期研究将中重度寻常型/落叶型天疱疮成人随机分配至口服rilzabrutinib 400mg每日两次(n=65)或安慰剂(n=66),联合激素≤0.5mg/kg/d治疗37周。预设敏感性分析(激素≤5mg/d、含全部观察和患者)支持BTK抑制为可行治疗途径。
要点
- 预设敏感性分析支持rilzabrutinib治疗天疱疮的可行性
- 不良事件两组相似,总体耐受性良好
核心结论
- 修正后主要终点(激素≤10mg/d且排除远期观察)未达到统计学显著。
- 预设敏感性分析(激素≤5mg/d、含全部观察和全部患者)支持BTK抑制为天疱疮可行治疗途径。
研究设计与样本
- 3期随机双盲安慰剂对照研究PEGASUS,成人18-80岁中重度寻常型/落叶型天疱疮患者1:1随机。
- rilzabrutinib 400mg每日两次(n=65)或安慰剂(n=66),联合激素≤0.5mg/kg/d,治疗37周。
主要发现
- 次要终点(减少激素用量、延长完全缓解持续时间、缩短至首次完全缓解时间)显示数值改善但无统计学显著性。
- 不良事件两组相似,rilzabrutinib总体耐受性良好。
关键数值与推荐
- 主要终点完全缓解定义为第29-37周达到完全缓解且激素剂量≤10mg/d。
- 预设敏感性分析采用激素剂量≤5mg/d、纳入全部观察和全部患者。
临床怎么用
- rilzabrutinib 400mg每日两次联合激素≤0.5mg/kg/d可用于中重度天疱疮的潜在治疗。
- 临床决策需结合主要终点未达显著而敏感性分析支持获益的结果综合判断。
局限性
- 主要终点采用修正后激素≤10mg/d且排除远期观察,未达统计学显著。
- 次要终点仅显示数值改善,无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRIAL DESIGN: Pemphigus is a rare but life-threatening autoimmune disease requiring long-term treatment that minimizes corticosteroid (CS) exposure while providing consistent disease control. The phase 2 pemphigus study of oral, reversible, covalent Bruton tyrosine kinase inhibitor rilzabrutinib demonstrated rapid and sustained efficacy with well-tolerated safety. METHODS: Adults (aged 18-80 years) were randomized 1:1 to 400 mg rilzabrutinib (n = 65) or placebo (n = 66) twice daily (with CS ≤ 0.5 mg/kg/d) for 37 weeks in the phase 3 PEGASUS study in moderate-to-severe pemphigus vulgaris/pemphigus foliaceus. RESULTS: The primary endpoint of complete remission from week 29 to week 37 with the amended endpoint CS dose ≤10 mg/d was not significant for 13 of 54 (24%) rilzabrutinib versus 10 of 55 (18%) placebo patients with PV (P = .45). Secondary endpoints showed numerical but nonsignificant improvements with rilzabrutinib (vs placebo) in reduced CS use, prolonged complete remission duration, and faster time to first complete remission. CONCLUSIONS: Overall, rilzabrutinib was well-tolerated, with similar adverse events reported in both groups. Using minimal CS dose ≤10 mg/d and excluding remote observations, the primary efficacy endpoint was not met. However, results from a prespecified sensitivity analysis using CS dose ≤5 mg/d, considering all observations, and including all patients support Bruton tyrosine kinase inhibition as a viable therapeutic approach for pemphigus.
引用
- Murrell DF, Caux F, Patsatsi A, et al. Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study. J Invest Dermatol. 2024. PMID: 38493933. doi:10.1016/j.jid.2024.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。